Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -3.04%10 PB Ratio is 1.25 as of Jul. 18, 2026, which is 17% below its 10-year median of 1.50. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Upstream Bio ranks better than 75.88% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-18), Upstream Bio's share price is $6.99. Upstream Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $5.59. Hence, Upstream Bio's PB Ratio of today is 1.25.
The historical rank and industry rank for Upstream Bio's PB Ratio or its related term are showing as below:
UPB'
s PB Ratio Range Over the Past 10 Years
Min: 0.73 Med: 1.5 Max: 4.96
Current: 1.25
During the past 4 years, Upstream Bio's highest PB Ratio was 4.96. The lowest was 0.73. And the median was 1.50.
UPB's PB Ratio is ranked better than 75.88% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs UPB: 1.25
During the past 12 months, Upstream Bio's average Book Value Per Share Growth Rate was -32.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Upstream Bio PB Ratio Related Terms
Upstream Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Upstream Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Upstream Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Upstream Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Upstream Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Upstream Bio (UPB) has a PB Ratio of 1.25 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Upstream Bio and its competitors. This is 17% below median its historical median of 1.50. Over the past decade, Upstream Bio's PB Ratio has ranged from 0.73 to 4.96. According to the industry distribution chart, Upstream Bio ranks #296 out of 1227 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Upstream Bio's PB Ratio too high?
Upstream Bio's current PB Ratio of 1.25 is 17% below median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 4.96. The Biotechnology industry median PB Ratio is 2.82. Upstream Bio's value of 1.25 is 55.7% below this industry median. Based on the distribution chart, Upstream Bio ranks #296 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's PB Ratio compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #296 out of 1227 companies for PB Ratio. This places Upstream Bio in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.82. Upstream Bio's value of 1.25 is 55.7% below this benchmark. Historically, Upstream Bio's own PB Ratio has ranged from 0.73 to 4.96 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 2.82, Upstream Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Upstream Bio's current PB Ratio of 1.25 is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Upstream Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Upstream Bio's current PB Ratio is 1.25, which is 17% below median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current PB Ratio of 1.25. The current PB Ratio is 1.25, which is 17% below median its 10-year median of 1.50 and 55.7% below the Biotechnology industry median of 2.82. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Upstream Bio (UPB), the current PB Ratio is 1.25 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
